Flow Cytometry of Hematological Malignancies

Flow cytometric analysis is often integral to the swift and accurate diagnosis of leukemias and lymphomas of the blood, bone marrow, and lymph nodes. However, in the fast-moving and expanding field of clinical hematology, in can be challenging to remain up to speed with the latest biological research and technological innovations. Flow Cytometry of Hematological Malignancies has been designed to provide all those working in hematological oncology with a practical, cutting-edge handbook, featuring clear and fully illustrated guidance on all aspects of cytometry’s role in diagnosis and analysis. This essential second edition includes:

    Explorations of more than 70 antigens 
    Full-color illustrations throughout 
    New descriptions of recently discovered markers 
    WHO classifications of hematological neoplastic diseases 
    Helpful tips for result interpretation and analysis

Featuring all this and more, Flow Cytometry of Hematological Malignancies, Second Edition, is an invaluable resource for both trainee and experienced hematologists, hematopathologists, oncologists, and pathologists, as well as medical students and diagnostic lab technicians.

CONTENTS

Foreword to the First Edition by Maryalice Stetler-Stevenson

Foreword to the First Edition by Bruno Brando

Foreword to the Second Edition by Michael J Borowitz

Preface to the First Edition

Preface to the Second Edition

1 ANTIGENS

Clustered (CD) Antigens

CD1 Antigens, XX

CD2 Antigen, XX

CD3 Antigen, XX

CD4 Antigen, XX

CD5 Antigen, XX

CD7 Antigen, XX

CD8 Antigen, XX

CD10 Antigen, XX

CD11b Antigen, XX

CD11c Antigen, XX

CD13 Antigen, XX

CD14 Antigen, XX

CD15 Antigen, XX

CD16 Antigen, XX

CD19 Antigen, XX

CD20 Antigen, XX

CD22 Antigen, XX

CD23 Antigen, XX

CD24 Antigen, XX

CD25 Antigen, XX

CD26 Antigen, XX

CD27 Antigen, XX

CD28 Antigen, XX

CD30 Antigen, XX

CD33 Antigen, XX

CD34 Antigen, XX

CD38 Antigen, XX

CD43 Antigen, XX

CD45 Antigen, XX

CD45 Isoforms, XX

CD48 Antigen, see SLAM molecules, XX

CD49 Antigens, XX

CD56 Antigen, XX

CD57 Antigen, XX

CD61 Antigen, XX

CD62L Antigen, XX

CD64 Antigen, XX

CD65 Antigen, XX

CD66c Antigen, XX

CD71 Antigen, XX

CD79 Antigen, XX

CD81 Antigen, XX

CD84 Antigen, see SLAM molecules, XX

CD103 Antigen, XX

CD123 Antigen, XX

CD117 Antigen, XX

CD138 Antigen, XX

CD150 Antigen, see SLAM molecules, XX

CD158 Antigen, see KIRs, XX

CD181-186, 191-199 Antigens, see Chemokines and Chemokine Receptors, XX

CD200 Antigen, XX

CD229 Antigen, see SLAM molecules, XX

CD244 Antigen, see SLAM molecules, XX

CD280-290 Antigens, see Toll-like Receptors, XX

CD305 Antigen, XX

CD307 (IRTA) Antigen Family, XX

CD319 Antigen, see SLAM molecules, XX

CD352-353 Antigens, see SLAM molecules, XX

CD371 Antigen, XX

Non clustered (or primarily known with other names) antigens

Bcl-2 Protein, XX

Chemokines and Chemokine Receptors, XX

CRLF2, XX

Cytotoxic Proteins, XX

HLA-DR Antigen, XX

Immunoglobulins, XX

KIR, CD158 Isoforms, XX

Myeloperoxidase (MPO), XX

NG2 Antigen, XX

PCA-1 Antigen, XX

ROR-1 Antigen, XX

SLAM Molecules and SLAM Associated Protein (SAP), XX

SOX11, XX

T-cell Receptor (TCR), XX

Terminal Deoxy-nucleotidyl Transferase (TdT), XX

Toll-like Receptors (TLR), XX

VS38 Antigen, XX

ZAP-70 Protein, XX

 

2 DISEASES

Myeloproliferative neoplasms, XXX

Chronic myeloid leukemia (CML), XXX

Myeloproliferative neoplasms other than CML, XXX

Chronic neutrophilic leukemia (CNL), XXX

Polycythemia vera (PV), XXX

Primary myelofibrosis (PMF), XXX

Essential thrombocythemia (ET), XXX

Chronic eosinophilic leukemia (CEL), XXX

Mastocytosis, XXX

Acute masT-cell leukemia (AMCL), XXX

Chronic masT-cell leukemia (CMCL), XXX

Myelomastocytic leukemia (MML), XXX

Myelodysplastic/myeloproliferative neoplasms, XXX

Chronic myelomonocytic leukemia (CMML), XXX

Other myelodysplastic/myeloproliferative neoplasms and related conditions, XXX

Juvenile myelomonocytic leukemia (JMML), XXX

Atypical CML bcr/abl negative (ACML), XXX

RAS-associated autoimmune leukoproliferative disorder (RALD), XXX

Myelodysplastic syndromes, XXX

Myeloid neoplasms with germline predisposition, XXX

Acute myeloid leukemias, XXX

AMLs with recurrent genetic anomalies, XXX

AMLs with chromosomal anomalies, XXX

AMLs with gene mutations, XXX

AMLs with recurrent genetic anomalies, not recognized by the WHO

classification, XXX

AMLs with myelodysplastic related changes (AML-MRC), XXX

AMLs not otherwise specified, XXX

AML with minimal differentiation, XXX

AML without maturation, XXX

AML with maturation, XXX

Acute myelomonocytic leukemia (AMMoL), XXX

Acute monoblastic or monocytic leukemia (AMoL), XXX

Pure erythroid leukemia (PEL), XXX

Acute megakaryoblastic leukemia (AMKL), XXX

Acute basophilic leukemia (ABL), XXX

Myeloid proliferations associated with Down syndrome, XXX

Transient abnormal myelopoiesis (TAM), XXX

AMLs in patients with Down syndrome, XXX

Blastic plasmacytoid dendritic cell neoplasm (BPDCN/PDCL), XXX

Acute leukemias with ambiguous lineage attribution (ALAL), XXX

Acute undifferentiated leukemias (AUL), XXX

Mixed phenotype acute leukemias (MPAL), XXX

Neoplastic diseases of B and T lymphatic precursors, XXX

B lymphoblastic leukemia/lymphoma,

not otherwise specified (B-ALL/LBLnos), XXX

B lymphoblastic leukemia/lymphoma with recurrent genetic anomalies, XXX

T lymphoblastic leukemia/lymphoma (T-ALL/LBL), XXX

Early T-cell precursors lymphoblastic leukemia (ETP-ALL), XXX

NK lymphoblastic leukemia/lymphoma (NK-ALL/LBL), XXX

Neoplastic diseases of mature B cells, XXX

Chronic lymphocytic leukemia/small

lymphocytic lymphoma (B-CLL/SLL), XXX

Familial B-CLL, XXX

Richter syndrome, XXX

Monoclonal B-cell lymphocytosis (MBL), XXX

B-cell prolymphocytic leukemia (B-PLL), XXX

Lymphoplasmacytic lymphoma (LPL), XXX

Heavy chain disease (HCD), XXX

Gamma heavy chain disease, XXX

Mu heavy chain disease, XXX

Alpha heavy chain disease, XXX

Hairy cell leukemia (HCL), XXX

Hairy cell leukemia, variant (HCL-v), XXX

Hairy cell leukemia, Japanese variant (HCL-J), XXX

Splenic diffuse red pulp lymphoma (SDRPL), XXX

Marginal zone lymphomas (MZL), XXX

Nodal marginal zone lymphoma (NMZL), XXX

Splenic marginal zone lymphoma (SMZL), XXX

Extranodal marginal zone lymphoma (EMZL/MALToma), XXX

Clonal B-cell lymphocytosis with MZL-like phenotype (CBL-MZ), XXX

Follicular lymphoma (FCL), XXX

Testicular follicular lymphoma, XXX

Duodenal type follicular lymphoma, XXX

Pediatric type follicular lymphoma, XXX

Primitive cutaneous follicular lymphoma (PCFL), XXX

Large B-cell lymphoma with IRF4 rearrangement, XXX

Mantle cell lymphoma (MCL), XXX

Blastic mantle cell lymphoma (BMCL), XXX

Leukemic non nodal mantle cell lymphoma, XXX

Diffuse large B-cell lymphomas (DLBCLs), XXX

DLBCL not otherwise specified (DLBCL nos), XXX

T-cell/histiocyte-rich B-cell lymphoma (THRLBCL), XXX

Primary DLBCL of the CNS (PCNSL), XXX

Primary cutaneous DLBCL, “leg type”, XXX

EBV(+) DLBCL nos, XXX

DLBCL associated with chronic inflammation (PAL), XXX

Lymphomatoid granulomatosis (LyG), XXX

Primary mediastinal B-cell lymphoma (PMBCL), XXX

Intravascular large B-cell lymphoma (IVBCL), XXX

ALK-positive large cell lymphoma (ALK(+) LBCL), XXX

Plasmablastic lymphoma (PBL), XXX

Primary effusion lymphoma (PEL), XXX

HHV8-associated lymphoproliferative disorders, XXX

Burkitt lymphoma (BL), XXX

Burkitt leukemia with immature phenotype, XXX

Burkitt-like lymphoma with 11q aberrations, XXX

High grade B-cell lymphoma (HGBL), XXX

Plasma cell neoplasms, XXX

Monoclonal gammopathies of undetermined significance (MGUS), XXX

Multiple myeloma (MM), XXX

Plasma cell leukemia (PCL), XXX

Neoplastic diseases of mature T and NK cells, XXX

T-cell prolymphocytic leukemia (T-PLL), XXX

T-cell large granular lymphocytic leukemia (T-LGL), XXX

Chronic lymphoproliferative disorders of NK cells (CLPD-NK/CNKL), XXX

Aggressive NK-cell leukemia (ANKL), XXX

Adult T-cell leukemia/lymphoma (ATLL), XXX

Extranodal NK/T-cell lymphoma, “nasal type” (ENKTL), XXX

Intestinal T-cell lymphoma (ITCL), XXX

Enteropathy-associated T-cell lymphoma (EATCL), XXX

Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), XXX

Indolent gastro-intestinal T lymphoproliferative disorder, XXX

Hepatosplenic T-cell lymphoma (HTSCL), XXX

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL), XXX

Mycosis fungoides (MF), XXX

Sézary syndrome (SS), XXX

Primary cutaneous CD30(+) lymphoproliferative disorders, XXX

Lymphomatoid papulosis (LyP), XXX

Primary cutaneous anaplastic T-cell lymphoma (cALCL), XXX

Primary cutaneous peripheral T-cell lymphoma (PTCL), XXX

Primary cutaneous TCRγδ(+) T-cell lymphoma (PCGD-TCL), XXX

Primary cutaneous CD8(+) aggressive epidermotropic

cytotoxic T-cell lymphoma, XXX

Primary cutaneous acral CD8(+) T-cell lymphoma

Primary cutaneous lymphoma of the medium/small CD4(+) T cells

 (PCSM-TCL), XXX

Peripheral T-cell lymphoma, not otherwise specified (PTCLnos), XXX

Nodal lymphomas of follicular T-helper derivation, XXX

Angioimmunoblastic T-cell lymphoma (AITL), XXX

Follicular T-cell lymphoma (FTCL), XXX

Nodal PTCL with follicular T-helper phenotype, XXX

Anaplastic large cell lymphoma ALK(+) (ALK(+) ALCL), XXX

Anaplastic large cell lymphoma ALK(-) (ALK(-) ALCL), XXX

Breast implant-associated anaplastic large cell lymphoma (biaALCL), XXX

Neoplastic diseases of histiocytic and dendritic cells, XXX

Histiocytic sarcoma (HS), XXX

Langerhans cell histiocytosis (LCH), XXX

Indeterminate dendritic cell tumor (IDCT), XXX

Interdigitating dendritic cell sarcoma (IDCS), XXX

Follicular dendritic cell sarcoma (FDCS), XXX

Erdheim-Chester disease (EDC), XXX

3 APPENDIX

Acute leukemias not recognized by the 2016 WHO classification, XXX

Acute leukemia of myeloid/NK precursors (M/NK-AL), XXX

Acute leukemia of myeloid dendritic cells (MDCL), XXX

Acute leukemia of Langerhans cells, XXX

Mature B-cell lymphoblastic leukemia, XXX

Composite lymphomas, XXX

Hypereosinophilic syndrome (HES), lymphocyte variant, XXX

Indolent T lymphoblastic proliferations (iT-LBP), XXX

Polyclonal lymphocytoses of B lymphocytes, XXX

Persistent polyclonal B-cell lymphocytosis (PPBL), XXX

Persistent polyclonal CD5(+) B-cell lymphocytosis, XXX

Persistent polyclonal B-cell lymphocytosis, Japanese (hairy) variant, XXX

Polyclonal plasmacytoses, XXX

Small round (blue) cell tumors (SR(B)CT), XXX

Index

Dr Claudio Ortolani, is an expert in the area of diagnosis of hematological malignancies. Now retired, Dr Ortolani was Consultant in the Department of Clinical Pathology at Venice General Hospital, Venice, Italy. He is one of the founding members of the Italian Society for Cytometric Cell Analysis (ISCCA), of whose board he is currently a member. He has taught and lectured internationally on how to use flow cytometry to aid in diagnosing hematological diseases